[1]袁紫东 王秋月.LPA/LPA1信号通路与糖尿病肾脏疾病[J].国际内分泌代谢杂志,2020,40(01):55-58.[doi:10.3760/cma.j.issn.1673-4157.2020.01.013]
　Yuan Zidong,Wang Qiuyue.LPA/LPA1 signaling pathway and diabetic kidney disease[J].International Journal of Endocrinology and Metabolism,2020,40(01):55-58.[doi:10.3760/cma.j.issn.1673-4157.2020.01.013]
点击复制

LPA/LPA1信号通路与糖尿病肾脏疾病()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
40
期数:
2020年01期
页码:
55-58
栏目:
基础研究
出版日期:
2020-01-20

文章信息/Info

Title:
LPA/LPA1 signaling pathway and diabetic kidney disease
作者:
袁紫东 王秋月
中国医科大学附属第一医院内分泌与代谢病科,沈阳 110001
Author(s):
Yuan Zidong;  Wang Qiuyue
Department of Endocrinology and Metabolism, The First Affiliated Hospital of China Medial University, Shenyang 110001, China
关键词:
溶血磷脂酸;  信号通路;  糖尿病肾脏疾病
Keywords:
Lysophosphatidic acid;  Signaling pathway;  Diabetic kidney disease
DOI:
10.3760/cma.j.issn.1673-4157.2020.01.013
摘要:
糖尿病肾脏疾病(DKD)是糖尿病常见的微血管并发症之一,是导致终末期肾病(ESRD)的主要原因。溶血磷脂酸/溶血磷脂酸受体1(LPA/LPA1)信号通路通过引发下游信号级联介导一系列病理过程,是多种疾病的重要调节通路。在DKD方面,LPA/LPA1信号通路可能在系膜细胞增殖、纤维化、足细胞损伤、炎性反应及氧化应激等多个环节发挥作用,进而促进DKD的疾病进展,但关于该通路在DKD发病的具体分子机制方面的报道有限。深入研究LPA/LPA1信号通路的作用对DKD的诊治具有重要意义。
Abstract:
Diabetic kidney disease(DKD)is one of the common microvascular complications of diabetes mellitus and is the leading cause of end-stage renal disease(ESRD). Lysophosphatidic acid/lysophosphatidic acid receptor 1(LPA/LPA1)signaling pathway mediates a series of pathological processes by triggering downstream signaling cascade and is an important regulatory pathway for many diseases. In terms of DKD, LPA/LPA1 signaling pathway may play a role in mesangial cell proliferation, fibrosis, podocyte injury, inflammation and oxidative stress to promote the progression of DKD. However, there are limited reports on the specific molecular mechanism of this pathway in the pathogenesis of DKD. In-depth study of the role of LPA/LPA1 signaling pathway is of great significance for the diagnosis and treatment of DKD.

参考文献/References:

[1] Lin YC,Chang YH,Yang SY,et al.Update of pathophysiology and management of diabetic kidney disease[J].J Formos Med Assoc,2018,117(8):662-675. DOI:10.1016/j.jfma.2018.02.007.
[2] Ilyas Z,Chaiban JT,Krikorian A.Novel insights into the pathophysiology and clinical aspects of diabetic nephropathy[J].Rev Endocr Metab Disord,2017,18(1):21-28. DOI:10.1007/s11154-017-9422-3.
[3] Valdés-Rives SA,González-Arenas A.Autotaxin-lysophosphatidic acid: from inflammation to cancer development[J].Mediators Inflamm,2017,2017:9173090.DOI:10.1155/2017/9173090.
[4] Hernández-Araiza I,Morales-Lázaro SL,Canul-Sánchez JA,et al.Role of lysophosphatidic acid in ion channel function and disease[J].J Neurophysiol,2018,120(3):1198-1211.DOI:10.1152/jn.00226.2018.
[5] Zhang MZ,Wang X,Yang H,et al.Lysophosphatidic acid receptor antagonism protects against fiabetic nephropathy in a type 2 diabetic model[J].J Am Soc Nephrol,2017,28(11):3300-3311.DOI:10.1681/ASN.2017010107.
[6] Gonzálezgil I, Zian D, Vázquez-Villa H, et al. The status of the lysophosphatidic acid receptor type 1(LPA1R)[J]. Med Chem Comm, 2015, 6(1): 13-23.DOI:10.1039/C4MD00333K.
[7] Yung YC,Stoddard NC,Mirendil H,et al.Lysophosphatidic acid signaling in the nervous system[J].Neuron,2015,85(4):669-682.DOI:10.1016/j.neuron.2015.01.009.
[8] Kim D, Li HY, Lee JH,et al. Lysophosphatidic acid increases mesangial cell proliferation in models of diabetic nephropathy via Rac1/MAPK/KLF5 signaling[J].Exp Mol Med,2019,51(2):18. DOI:10.1038/s12276-019-0217-3.
[9] Wang D,Guan MP,Zheng ZJ,et al.Transcription factor Egr1 is involved in high glucose-induced proliferation and fibrosis in rat glomerular mesangial cells[J].Cell Physiol Biochem,2015,36(6):2093-2107.DOI:10.1159/000430177.
[10] Ray U,Roy SS.Aberrant lipid metabolism in cancer cells-the role of oncolipid-activated signaling[J].FEBS J,2018,285(3):432-443.DOI:10.1111/febs.14281.
[11] Ilatovskaya DV, Levchenko V, Lowing A,et al. Podocyte injury in diabetic nephropathy: implications of angiotensin Ⅱ-dependent activation of TRPC channels[J].Sci Rep,2015,5:17637. DOI:10.1038/srep17637.
[12] Nagata M. Podocyte injury and its consequences[J].Kidney Int,2016,89(6):1221-1230. DOI:10.1016/j.kint.2016.01.012.
[13] Azushima K,Gurley SB,Coffman TM.Modelling diabetic nephropathy in mice[J].Nat Rev Nephrol,2018,14(1):48-56.DOI:10.1038/nrneph.2017.142.
[14] Humphreys BD.Mechanisms of renal fibrosis[J].Annu Rev Physiol,2018,80:309-326.DOI:10.1146/annurev-physiol-022516-034227.
[15] Palmer SM,Snyder L,Todd JL,et al.Randomized, double-blind, placebo-controlled, phase 2 trial of BMS-986020, a lysophosphatidic acid receptor antagonist for the treatment of Idiopathic pulmonary fibrosis[J].Chest,2018,154(5):1061-1069.DOI:10.1016/j.chest.2018.08.1058.
[16] Castelino FV,Bain G, Pace VA,et al. An autotaxin/lysophosphatidic acid/interleukin-6 amplification loop drives scleroderma fibrosis[J].Arthritis Rheumatol,2016,68(12):2964-2974. DOI:10.1002/art.39797.
[17] Michalczyk A,Dogowska B,Heryc' R,et al. Associations between plasma lysophospholipids concentrations, chronic kidney disease and the type of renal replacement therapy[J].Lipids Health Dis,2019,18(1):85.DOI:10.1186/s12944-019-1040-5.
[18] Stoddard NC,Chun J.Promising pharmacological directions in the world of lysophosphatidic acid signaling[J].Biomol Ther(Seoul),2015,23(1):1-11.DOI:10.4062/biomolther.2014.109.
[19] Pichler R,Afkarian M,Dieter BP,et al. Immunity and inflammation in diabetic kidney disease: translating mechanisms to biomarkers and treatment targets[J].Am J Physiol Renal Physiol,2017,312(4):F716-F731.DOI:10.1152/ajprenal.00314.2016.
[20] Volpe CMO,Villar-Delfino PH,Dos Anjos PMF,et al.Cellular death, reactive oxygen species(ROS)and diabetic complications[J].Cell Death Dis,2018,9(2):119.DOI:10.1038/s41419-017-0135-z.
[21] Vidya MK,Kumar VG,Sejian V,et al.Toll-like receptors: significance, ligands, signaling pathways, and functions in mammals[J].Int Rev Immunol,2018,37(1):20-36.DOI:10.1080/08830185.2017.1380200.
[22] Garibotto G,Carta A,Picciotto D,et al.Toll-like receptor-4 signaling mediates inflammation and tissue injury in diabetic nephropathy[J].J Nephrol,2017,30(6):719-727.DOI:10.1007/s40620-017-0432-8.
[23] Zhu L,Han J,Yuan R,et al.Berberine ameliorates diabetic nephropathy by inhibiting TLR4/NF-κB pathway[J].Biol Res,2018,51(1):9.DOI:10.1186/s40659-018-0157-8.
[24] Nadeem A,Ahmad SF,Bakheet SA,et al.Toll-like receptor 4 signaling is associated with upregulated NADPH oxidase expression in peripheral T cells of children with autism[J].Brain Behav Immun,2017,61:146-154.DOI:10.1016/j.bbi.2016.12.024.
[25] Lee JH,Sarker MK,Choi H,et al.Lysophosphatidic acid receptor 1 inhibitor, AM095, attenuates diabetic nephropathy in mice by downregulation of TLR4/NF-κB signaling and NADPH oxidase[J].Biochim Biophys Acta Mol Basis Dis,2019,1865(6):1332-1340. DOI:10.1016/j.bbadis.2019.02.001.
[26] Shimizu M,Furuichi K,Toyama T,et al.Serum autotaxin levels are associated with proteinuria and kidney lesions in Japanese type 2 diabetic patients with biopsy-proven diabetic nephropathy[J].Intern Med,2016,55(3):215-221.DOI:10.2169/internalmedicine.55.5473.
[27] Saulnier-Blache JS,Feigerlova E,Halimi JM,et al.Urinary lysophopholipids are increased in diabetic patients with nephropathy[J].J Diabetes Complications,2017,31(7):1103-1108.DOI:10.1016/j.jdiacomp.2017.04.024.

相似文献/References:

[1]林楚曼 林伟浩 周蕊 杨力.GLP-1缓解非酒精性脂肪性肝病相关信号通路的研究进展[J].国际内分泌代谢杂志,2018,38(03):179.[doi:10.3760/cma.j.issn.1673-4157.2018.03.009]
　Lin Chuman*,Lin Weihao,Zhou Rui,et al.The research progresses on GLP-1 related signal pathways in alleviating non-alcoholic fatty liver disease[J].International Journal of Endocrinology and Metabolism,2018,38(01):179.[doi:10.3760/cma.j.issn.1673-4157.2018.03.009]
[2]贺琼 薄佳琪 张梦圆 王维 何传辉 刘云峰.骨膜蛋白在糖尿病心肌病发病中的作用[J].国际内分泌代谢杂志,2020,40(04):271.[doi:10.3760/cma.j.issn.1673-4157.2020.04.013]
　He Qiong,Bo Jiaqi,ZhangMengyuan,et al.Role of periostin in the pathogenesis of diabetic cardiomyopathy[J].International Journal of Endocrinology and Metabolism,2020,40(01):271.[doi:10.3760/cma.j.issn.1673-4157.2020.04.013]

备注/Memo

备注/Memo:
通信作者:王秋月,Email:wqycmu123@163.com
基金项目:辽宁省高等学校“高端人才队伍建设工程”项目([2014]187); 辽宁省自然科学基金(201602862)
Corresponding author: Wang Qiuyue,Email:wqycmu123@163.comProject"([2014]187); National Natural Science Foundation of Liaoning Province(201602862)
更新日期/Last Update: 2020-01-20